drugset / Trial / NCT03706521

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

NCT03706521 ↗

Phase 2 Terminated 13 enrolled Biosplice Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and efficacy of lorecivivint (LOR) injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects. Efficacy was primarily evaluated via magnetic resonance imaging (MRI).

Timeline

Start
2019-03-11
Primary completion
2020-07-22
Completion
2020-12-21

Outcome

Outcome not reported

Stopped: “The study was terminated early due to COVID-19 pandemic-related issues (e.g., temporary site closures impacting data collection). No formal Statistical Analysis Plan was prepared, and the study report was finalized without any statistical analysis.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorecivivint Small molecule 0.07 mg Other

Indications